Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing protein-based therapeutics, has named Abbie Celniker, Ph.D., chief executive officer.
Celniker brings more than 20 years of experience in building late-stage protein therapeutic discovery and development programs and biologics-focused businesses to Eleven Biotherapeutics. Most recently, Celniker served as president and chief executive officer at Taligen Therapeutics, which was acquired by Alexion in January 2011.
Eleven Biotherapeutics has also named Chen Schor as chief business officer. Schor will replace interim chief business officer, Cary Pfeffer, M.D.
Most recently, Schor served as vice president, business development, global branded products at Teva Pharmaceutical where he led the expansion of the company's branded pipeline in multiple therapeutic areas.